Asparaginase is one of the most important chemotherapeutic agents against pediatric acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. The therapeutic efficacy (e.g., chemoresistance) and adverse effects of asparaginase (e.g., hypersensivity and pancreatitis) have been investigated over the past four decades. It was suggested early on that leukemic cells are resistant to asparaginase because of their increased asparagine synthetase activity. Afterward, other mechanisms associated with asparaginase resistance were reported. Not only leukemic cells but also patients themselves may play a role in causing asparaginase resistance, which has been associated with unfavorable outcome in children with ALL. This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. An estimated 6000 new cases of ALL are diagnosed yearly in the United States; roughly 60% of cases occur in people aged younger than 20 years. 1 Recent advances in intensive chemotherapy, as well as adequate supportive care, have made significant improvements in childhood ALL, so that approximately 80% of the children are cured (Table 1) . 2e11 According to the registry of the Taiwan Childhood Cancer Foundation, there are about 130e140 newly diagnosed ALL children (younger than 18 years), accounting for 25% of all childhood cancers in Taiwan. The treatment of childhood ALL in Taiwan has improved during the past decade. Overall survival improved significantly from 75.5% in 1997e2001 to 83.5% in 2002e2007. 10 The high cure rate for ALL is attributable to the improved supportive care, more precise risk stratification, and personalized chemotherapy based on the characteristics of leukemic cells and hosts. 12 Asparaginase is an enzyme isolated from various natural sources. However, only Escherichia coli and Erwinia chrysanthemi asparaginase are currently available for medical use. Polyethylene glycol (PEG)easparaginase is a conjugate of the native E. coli asparaginase covalently linked to PEG at sites not affecting enzymatic activity. The characteristics of various asparaginase preparations are summarized in Table 2 . Asparaginase has been highly successful for inducing remissions in acute leukemia since 1967. 13 Asparaginase exerts its antileukemic activity by converting asparagine to aspartic acid in the extracellular fluid.
14 Most normal cells can synthesize asparagine, but leukemic lymphoblasts are sensitive to the depletion of extracellular asparagine, putatively because they express low levels of asparagine synthetase (ASNS) 15e17 or they lack the ability to upregulate the expression of ASNS when exposed to asparaginase. 18, 19 The relative inability of leukemic lymphoblasts to produce their own asparagine to compensate for the shortage of extracellular asparagine reduces asparagine-dependent protein synthesis, resulting in leukemic cell death. 20 Extensive clinical data support the benefit of intensive asparaginase treatment compared with less intensive regimens in pediatric ALL. 21e23 Resistance to asparaginase has been demonstrated to be an unfavorable prognostic factor.
24e27 One may reasonably postulate that resistant leukemic cells would have accesses to increase their asparagine in sufficient quantity to meet their needs. In recent years, considerable effort has been made to address fundamental questions about the role of ASNS in asparaginase resistance. However, data from some recent studies on the importance of ASNS are conflicting (Table 3 ). In addition to the leukemic cells, there is increasing evidence of host factors that can affect asparaginase resistance. In this article, the mechanisms contributing to asparaginase resistance will be reviewed.
Baseline high ASNS expression level in leukemic cells
Horowitz et al 15 reported experiments on the ASNS activity of several transplanted mouse leukemias. Seven different y Nalm20, Nalm21, Nalm29, Nalm30, SUP-B15, HB, RS411, BV173, HAL, UOC, MV, Nalm27, Nalm6, REH, 697, RCH-ACV.
asparaginase-sensitive mouse leukemias proved to have no or only slight ASNS activity. In contrast, asparaginaseresistant leukemias showed appreciable ASNS activity. Haskell and Canellos 16 studied the ASNS levels in 18 leukemia patients who were subsequently treated with asparaginase. They found that the ASNS in leukemic cells was nearly undetectable prior to therapy regardless of subsequent response to asparaginase treatment, although the ASNS level in the asparaginase-resistant group was slightly higher than in the asparaginase-sensitive group. Kiriyama et al 17 later showed that asparaginase-sensitive human leukemic cell lines exhibited a lower baseline ASNS level than asparaginase-nonsensitive ones. ASNS was also reported as one of the top genes with at least 2-fold expression level in two resistant T-ALL cell lines at different maturation stages. 17 Gene expression profiling studies by microarray analysis revealed conflicting results. Scherf et al 28 showed that six leukemic cell lines had very high negative correlation between the ASNS expression and asparaginase sensitivity. Holleman et al 29 found that ASNS was one of the genes discriminating asparaginase-sensitive and asparaginaseresistant leukemic cells from newly diagnosed pediatric ALL patients. Fine et al 30 demonstrated that ASNS was one of the genes that had different asparaginase-sensitive and asparaginase-resistant cell lines in accordance with previous reports. However, baseline ASNS expression was not associated with asparaginase sensitivity in clinical ALL samples.
The t(12;21)þ ALL, which harbors the TEL/AML1 gene fusion and accounts for about 25% of pediatric ALL, was found to be significantly related to in vitro drug sensitivity for asparaginase. 31 The simple paradigm would be sensitivity to asparaginase in t(12;21)þ ALL emerged via a low baseline expression of ASNS. Surprisingly, Stams et al 32 showed that the expression of ASNS in t(12;21)þ ALL was significantly higher than in t(12;21) ALL. The ASNS expression did not differ in sensitive and resistant t(12;21)þ ALL, either. The same trend was also demonstrated by Krejci et al. 33 Both studies had only a small number of patient samples and used real-time quantitative polymerase chain reaction (RTQ-PCR) to determine ASNS mRNA expression. Although ASNS expression was not linked to asparaginase resistance in t(12;21)þ ALL, Stams et al 34 later reported that the ASNS expression determined by either RTQ-PCR or microarray significantly differed between sensitive and resistant t(12;21)þ ALL. With a larger sample size and microarray analysis, a different result was shown by Iwamoto et al. 35 The ASNS expression levels were found to be significantly lower in t(12;21)þ ALL compared to t(12;21) ALL.
Notably, the quantification of ASNS expression in leukemic cells by mRNA is limited by the fact that the relationship between the ASNS mRNA and intracellular protein concentrations in primary ALL has not been established. Su In conclusion, a different sample size, determination of gene expressions, and origin of sample may account for the discrepancy in the results. However, these studies indicate that the baseline ASNS level plays a role but is not the only factor for leukemic cells' resistance to asparaginase.
Upregulation of ASNS expression in leukemic cells in asparagine-depleted environment
In nine leukemia patients with paired ASNS activity determination before and during/after asparaginase treatment, the asparaginase-sensitive group showed no change in ASNS with therapy; however, there was a 7-fold increase in the mean level of ASNS levels in the asparaginase-resistant group. 16 The difference between the ASNS levels in the sensitive and resistant groups, determined during/after asparaginase treatment, was highly significant.
Hutson et al 19 also demonstrated that resistance to asparaginase in leukemic cell lines was mediated in vitro by an upregulation of ASNS expression in response to asparagine depletion of the culture medium. Aslanian et al 18 further examined the reversibility of the upregulation of ASNS caused by asparaginase treatment in asparaginaseresistant leukemic cells. They found that the elevated ASNS expression in the resistant cells was not fully reversed even 6 weeks after asparaginase had been removed from the culture medium.
However, asparaginase-sensitive leukemic cells were later revealed also to upregulate ASNS after asparaginase treatment. Stams et al 32 exposed samples from t(12;21)þ and t(12;21) ALL patients in vitro to asparaginase. Almost all samples showed upregulation of ASNS, which was independent from t(12;21) status and cellular sensitivity to asparaginase. Appel et al 38 also demonstrated that the upregulation of ASNS occurred in both sensitive and resistant cases within 24 hours of in vivo exposure to asparaginase. These data imply that mechanisms other than upregulated expression levels of ASNS contribute to cellular asparaginase resistance.
Increased substrates for ASNS reaction in leukemic cells
Aslanian and Kilberg 39 found that multiple adaptive changes affect the ASNS substrate availability in asparaginaseresistant leukemic cell line. These changes appear to support increased asparagine biosynthesis by increasing the intracellular levels of aspartate and glutamine. Asparaginaseresistant cells produced more glutamine by an increase in glutamine synthetase (GS) activity. These cells also enhanced the uptake of extracellular glutamine via secondary active Na þ -dependent transporters. However, there was little or no aspartate uptake by these cells. Recently, Appel et al 25 demonstrated that the levels of intracellular amino acids did not significantly differ among different in vitro sensitivity cases or in vivo clinical responders. Therefore, the contribution of the ASNS substrate, aspartate, and glutamine's resistance to asparaginase remains unclear.
Influence on protein synthesis and apoptosis in leukemic cells
Protein synthesis is fundamental in all living cells, both benign and malignant. Amino acid deficiency impairs protein synthesis and leads to apoptosis and cell death. Many tRNA syntheses and amino acid transporters were shown to increase expression in human cells with amino acid starvation. 30 In asparaginase-resistant ALL cells, several ribosomal protein genes were overexpressed, indicating the possible role of protein synthesis in asparaginase resistance. 29 Holleman et al 40 further analyzed the expression patterns of 70 apoptosis genes and tested the association between the expression of these genes and in vitro drug resistance in B-lineage ALL cells. Of the 70 apoptosis genes, three were associated with asparaginase resistance. Overexpression of BCL2L13, one of the genes associated with asparaginase resistance, was also associated with an unfavorable clinical outcome.
Host factors
There is increasing interest in the host factors resulting in asparaginase resistance of leukemic cells. Iwamoto et al 35 described the protective effect of mesenchymal cells in leukemic cells against asparaginase treatment in bone marrow microenvironment. They showed that bone marrow mesenchymal cells express significantly higher amounts of ASNS than leukemic cells. They then showed that the resistance of leukemic cell lines and some specimens of primary leukemia to asparaginase correlated with the expression of ASNS by mesenchymal cells. Forced increased expression of ASNS by the mesenchymal cell leads to increased resistance of the ALL cells; conversely, reduced expression of ASNS by the mesenchymal cell leads to enhanced sensitivity of the ALL cells.
The childhood obesity problem has become epidemic in the United States and other industrialized countries. In vivo and in vitro models have shown that obesity impairs the efficacy of chemotherapeutics against ALL cells, likely mediated by adipocytes. 41 Ehsanipour et al 42 examined bone marrow biopsy specimens from four obese and four lean adolescent leukemia patients for expression of ASNS and GS. They found that the GS expression was markedly increased in bone marrow adipocytes after induction chemotherapy, whereas ASNS expression appeared to be unaltered after treatment. They further cultured ALL cells over fibroblasts or adipocytes in media with asparaginase. They observed that adipocytes protected ALLs from asparaginase treatment via release of glutamine, which complemented the previous finding from Iwamoto et al. 35 The protective effect from such microenvironment is still open to debate.
In recent years, pharmacogenetics/pharmacogenomics in childhood ALL has become a major field of research. The genetic variation is a key determinant for the interindividual differences in treatment resistance. Luo et al 43 identified that the single nucleotide polymorphism in the promotor region of the ASNS gene, e92G>A, is associated with increased ASNS expression and is more common in pediatric leukemic patients than among normal control individuals. We used an agnostic genome-wide approach to identify inherited genomic variants that contribute to asparaginase resistance using normal lymphoblastoid cell lines from 87 trio members of European ancestry and 54 primary ALL leukemic blast samples at diagnosis. 44 We found that the top-ranked pathway was that of aspartate metabolism, which may be linked directly to the mechanism of action of asparaginase. The two most highly ranked genes (ADSL and DARS ) in this pathway encompassed seven single nucleotide polymorphisms. Moreover, we found that more sensitive ALL subtypes (hyperdiploid and TEL-AML1) had lower ADSL expression than the more resistant subtypes (T-ALL), which is consistent with higher ADSL expression associated with resistance.
Because asparaginase is a foreign protein, hypersensitivity reactions due to antiasparaginase antibody production are common, occurring in up to 45% of patients. 45 The development of these antibodies appears to be more commonly observed in native E. coli asparaginase than in the pegylated enzyme. 46 The development of antiasparaginase antibodies may shorten the half-life of asparaginase, prevent or delay absorption after intramuscular injection of asparaginase, or interfere with asparaginase activity.
47e49 Therefore, it confers resistance to asparaginase therapy and reduced therapeutic efficacy in some clinical studies.
50,51

Conclusion
The intensive administration of asparaginase improved the treatment outcomes in children with ALL. It is crucial to recognize the mechanisms for the development of both in vitro and in vivo resistance by leukemic cells. The role of the host factor is increasing. Adequate asparaginase exposure may result in a lower clearance of steroids, which may potentiate the cytotoxicity of vincristine. Therefore, it is important for clinicians to choose the appropriate management in patients with asparaginase resistance. Switching to another preparation may be a difficult choice. Measurement of asparaginase level during asparaginase treatment may help to guide the decision of switching preparations or dose escalation. Further studies should continue investigating and promoting effective asparaginase therapy individually.
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